

# **Test Definition: FPAIG**

Plasminogen Activator Inhibitor-1, 4G/5G Genotyping (PAI-1 Polymorphism)

# Overview

# Method Name

Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) technologies.

#### NY State Available

Yes

# Specimen

Specimen Type Whole blood

# **Specimen Required**

Specimen Type: Whole Blood
Preferred: EDTA
Acceptable: ACD (Yellow top)
Specimen volume: 5 mL
Collection Instructions: Draw 5 mL whole blood in a lavender top (EDTA) or yellow top (ACD) tube. Send refrigerated.

#### Forms

**New York Clients - Informed consent is required.** Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing is available in Special Instructions.

# Specimen Minimum Volume

1.00 mL

# **Reject Due To**

Hemolysis	NA
Lipemia	NA
Icteric	NA
Other	NA

# **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Whole blood	Ambient	8 days	
	Refrigerated (preferred)	8 days	



# **Test Definition: FPAIG**

Plasminogen Activator Inhibitor-1, 4G/5G Genotyping (PAI-1 Polymorphism)

# **Clinical & Interpretive**

#### **Clinical Information**

The PAI-1 4G allele is an inherited characteristic. If the polymorphism is present in a heterozygous or homozygous fashion, we recommend that the patient and their family consider genetic counseling to obtain additional information on inheritance and to identify other family members at risk.

If a patient possesses two or more congenital or acquired risk factors, the risk of disease may rise to more than the sum of the risk ratios for the individual risk factors. For instance, a combination of the 4G/4G genotype and the insulin resistance syndrome may confer an increase in cardiovascular disease risk over that conferred by the presence of an isolated PAI-1 4G/4G polymorphism.

#### Cautions

Genetic testing by PCR provides exceptionally high sensitivity and specificity. Incorrect genotyping results can be caused by rare polymorphisms in primer binding sites and to misidentification of specimens by collectors or laboratory personnel. This assay analyzes only the PAI 4G/5G locus and does not measure genetic abnormalities elsewhere in the genome.

#### **Clinical Reference**

Barcellona D. Thromb Haemost. 2003;90:1061.;Dossenbach-Glaninger. Clin Chem. 2003;49:1081.; Kohler et al. NEJM. 200;342:1792.; Margaglione M et al. Arterioscl Thromb and Vasc Bio. 1998;18:152.

# Performance

# **Method Description**

Patient DNA was evaluated for the PAI-1 4G/5G promoter polymorphism, which is a single base pair guanine (4G/5G) deletion/insertion polymorphism, using polymerase chain reaction (PCR) technology and restriction fragment length polymorphism (RFLP).

#### **PDF Report**

No

Day(s) Performed Wednesday, Saturday

Report Available 7-14 days

**Performing Laboratory Location** Esoterix Coagulation



# **Test Definition: FPAIG**

# Plasminogen Activator Inhibitor-1, 4G/5G Genotyping (PAI-1 Polymorphism)

# Fees & Codes

#### Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.

#### **Test Classification**

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

#### **CPT Code Information**

81400

# LOINC<sup>®</sup> Information

Test ID	Test Order Name	Order LOINC <sup>®</sup> Value
FPAIG	PAI-1 Gene Polymorphism	Not Provided
Result ID	Test Result Name	Result LOINC <sup>®</sup> Value

Z4765	PAI-1 Locus 4G/5G Polymorphism	Not Provided
Z4766	Results	52757-2
Z4767	Interpretation	Not Provided
Z4768	Comments	77202-0